Publications by authors named "Irma Olarte-Carrillo"

Polyvinyl alcohol (PVA) hydrogels have a wide range of applications in the pharmaceutical and biomedicine fields due to their exceptional biophysical properties. The study focuses on preparing and characterizing capsule-shaped PVA hydrogels to enhance their biocompatibility and porosity for controlled glucose release and cell proliferation. The hydrogels were prepared using different concentrations (Cs) and molecular weights (MWs) of PVA, with two different lengths, A (10 mm) and B (20 mm), to control glucose release over 60 min.

View Article and Find Full Text PDF
Article Synopsis
  • - Current therapies for chronic myeloid leukemia (CML) have significantly improved life expectancy, but there is limited knowledge about molecular changes besides the BCR::ABL1 fusion gene.
  • - The study aimed to explore the relationship between genetic variations in microRNA biogenesis and susceptibility to CML, analyzing data from 296 CML patients and 485 healthy individuals.
  • - Results showed that the variant rs13078 was more prevalent in CML patients, while rs7813 and rs2740349 were linked to poorer prognosis and later age of diagnosis, indicating that microRNA biogenesis pathways might contribute to CML genetic risk.
View Article and Find Full Text PDF

Background: Obesity has been associated with a low-grade proinflammatory state, and it has been related to the development of cancer in general, including hematologic cancer.

Aim: The present work aimed to identify the association of the diagnosis of obesity according to the body mass index (BMI) with prognostic factors of adult patients with Acute Lymphoblastic Leukemia (ALL).

Patients And Method: This observational, retrospective study included hospitalized patients diagnosed with ALL of the B-cell lineages.

View Article and Find Full Text PDF

IL-15 is a proinflammatory myokine essential for activating NK cells and CD8+ T lymphocytes, and its overexpression has been related to reducing overall survivorship in patients with acute lymphoblastic leukemia (ALL). Physical exercise has been shown to be safe, feasible, and beneficial in hematological cancers. Exercise requires the activation of muscles that secrete cytokines, such as IL-15, causing immune mobilization.

View Article and Find Full Text PDF

Introduction: In this study, we utilized the pulsed photoacoustic (PA) technique to analyze globular sedimentation in whole human blood, with a focus on distinguishing between healthy individuals and those with hemolytic anemia.

Methods: Blood samples were collected from both healthy individuals (women and men) and those with hemolytic anemia, and temporal and spectral parameters of PA signals were employed for analysis.

Results: Significant differences (p < 0.

View Article and Find Full Text PDF

Acute lymphoblastic leukemia (ALL) represents around 25% of adult acute leukemias. Despite the increasing improvement in the survival rate of ALL patients during the last decade, the heterogeneous clinical and molecular features of this malignancy still represent a major challenge for treatment and achieving better outcomes. To identify aberrantly expressed genes in bone marrow (BM) samples from adults with ALL, transcriptomic analysis was performed using Affymetrix Human Transcriptome Array 2.

View Article and Find Full Text PDF

Use of the potent tyrosine kinase inhibitor imatinib as the first-line treatment in chronic myeloid leukemia (CML) has decreased mortality from 20% to 2%. Approximately 30% of CML patients experience imatinib resistance, however, largely because of point mutations in the kinase domain of the BCR-ABL1 fusion gene. The aim of this study was to use next-generation sequencing (NGS) to identify mutations related to imatinib resistance.

View Article and Find Full Text PDF

Background: Leukemia is a neoplasm with high incidence and mortality rates. Mitotic death has been observed in tumor cells treated with chemotherapeutic agents. Ras family proteins participate in the transduction of signals involved in different processes, such as proliferation, differentiation, survival, and paradoxically, initiation of cell death.

View Article and Find Full Text PDF

Objective: In the last two years progress was made in molecular, physio pathological understanding and the form of transmission of COVID-19, and different therapeutic strategies have been explored to deal with the situation of the pandemic. However, the evaluation of certain genes that participate in the metabolism and transport of these drugs has not been fully explored. A lack of response to treatment and a lower survival have been observed that may be due to the presence of the drug resistance gene.

View Article and Find Full Text PDF

Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge of the molecular biology and the prognostic assessment of MF. Conventional treatment has limited impact on the patients' survival; it includes a wait-and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agents for anemia, cytoreductive drugs such as hydroxyurea for the splenomegaly and constitutional symptoms, and splenectomy or radiotherapy in selected patients.

View Article and Find Full Text PDF
Article Synopsis
  • - The consensus aims to provide health professionals across public institutions in Mexico with the latest and most important information regarding the diagnosis and treatment of chronic myeloproliferative neoplasms.
  • - It seeks to enhance the quality of care for patients dealing with these diseases nationwide.
  • - The initiative also aims to standardize diagnostic and treatment criteria for various myeloproliferative diseases among healthcare providers.
View Article and Find Full Text PDF
Article Synopsis
  • - Major thrombotic complications in myeloproliferative neoplasms (MPNs) are serious issues that can lead to high sickness rates and even death, complicating treatment.
  • - The occurrence of thrombosis indicates the need for thorough risk assessment and may require adjusting treatment plans, including the use of medications to prevent further clotting issues.
  • - Thrombosis is more common when MPNs are first diagnosed, especially in arteries, and once a thrombosis happens, there's a significant chance (20-33%) that it can happen again in the same area.
View Article and Find Full Text PDF

In addition to symptoms secondary to splenomegaly, microvascular abnormalities, and thrombohemorrhagic complications, patients with MPN may experience a significant symptom burden attributed to an increase in circulating inflammatory cytokines. These symptoms can be severe and limit quality of life. Therefore, in addition to the prevention of complications, one of the objectives of the treatment of MPN is the control of symptoms.

View Article and Find Full Text PDF

Patients with myeloproliferative neoplasms have an increased risk of thrombosis and bleeding. This risk must be identified, as well as individualizing the therapeutic strategy before invasive procedures; adequate cytoreduction reduces the risk of complications.

View Article and Find Full Text PDF

Polycythemia vera (PV) is mainly characterized by erythrocytosis, thrombotic and hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic progression and/or leukemic evolution over time. The diagnosis is made based on the 2016 WHO criteria. The treatment of PV focuses on rapidly reducing the erythrocyte mass, either by means of phlebotomies or with cytoreductive treatment, and the reduction of thrombotic risk by correcting cardiovascular risk factors and the use of platelet antiaggregants.

View Article and Find Full Text PDF

Myeloproliferative neoplasms (MPN) are associated with a significant risk of thrombosis and the hypercoagulable environment of pregnancy increases this risk. The most frequent gestational complications consist of spontaneous abortion, thrombosis, bleeding, and hypertensive disease of pregnancy. Treatment depends on thrombotic risk, gestational trimester, and myeloproliferative neoplasm.

View Article and Find Full Text PDF

The objective of this work is to generate recommendations on the management of allogeneic stem cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic review of articles published between 1999 and 2015 (January) was used as a source of scientific evidence. The recommendations were produced through a Delphi process involving a panel of 23 experts appointed by the European LeukemiaNet and the European Blood and Marrow Transplantation Group.

View Article and Find Full Text PDF

Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis in peripheral blood and an increase in the number of mature megakaryocytes in the bone marrow. In addition to marked thrombocytosis, it is characterized by increased thrombotic or hemorrhagic risk and the presence of constitutional symptoms. Patients with ET have a low but known risk of disease progression to myelofibrosis and/or acute leukemia.

View Article and Find Full Text PDF
Article Synopsis
  • Acute lymphoblastic leukemia (ALL) is linked to both genetic and environmental factors, with single nucleotide polymorphisms (SNPs) in specific genes potentially increasing risk in pediatric populations in Mexico.
  • A multicenter study was conducted comparing children diagnosed with ALL to healthy controls, examining the impact of SNPs rs2910164, rs12803915, rs11614913, and rs3746444 through DNA analysis.
  • The results indicated a significant association of the rs3746444 SNP with a higher risk of developing ALL, particularly in males, highlighting the need for further research on the genetic mechanisms behind ALL.
View Article and Find Full Text PDF

Background: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by different genetic alterations that cause changes in the normal mechanisms of differentiation, which are associated with chemoresistance. The ABCB1 gene is part of a family of ATP-binding cassette (ABC) transporter genes involved in the progression of various types of cancer. The following work aimed to evaluate the expression levels of the ABCB1 gene and the C3435T SNP with the response to first-line treatment and survival in patients with AML.

View Article and Find Full Text PDF
Article Synopsis
  • Various blood count biomarkers, specifically the neutrophil-to-lymphocyte (NLR) and monocyte-to-lymphocyte (MLR) ratios, are useful for predicting outcomes in critically ill COVID-19 patients.
  • A study of 125 patients found that high NLR (>13) and MLR (>0.5) values were significantly linked to increased mortality risk, while lymphocyte-to-platelet ratio (LPR) showed no significant impact.
  • The findings suggest that monitoring NLR and MLR can help identify high-risk patients needing more intensive care for COVID-19.
View Article and Find Full Text PDF
Article Synopsis
  • The treatment of acute lymphoblastic leukemia (ALL) typically involves using multiple drugs to achieve complete remission while certain prognostic factors can help identify high-risk patients for relapse.
  • A study analyzed the impact of specific risk factors—ABCB1 gene overexpression, favorable steroid response, and early treatment response—on patient outcomes in adults with B-ALL without major genetic abnormalities.
  • Results indicated that while ABCB1 levels did not directly affect the induction response, a favorable steroid response and early response on day +8 significantly correlated with better outcomes; having more than two negative factors was linked to treatment failure.
View Article and Find Full Text PDF
Article Synopsis
  • Metformin shows potential as an adjunctive treatment for Acute Lymphoblastic Leukemia (ALL), enhancing the cancer-fighting effects of chemotherapy.
  • A study involving 123 patients revealed that those treated with metformin experienced a lower relapse rate (6.5%) compared to those receiving standard chemotherapy alone (17.1%).
  • Overall survival and disease-free survival rates were 43% and 47%, respectively, indicating that metformin might improve outcomes for ALL patients regardless of their initial biological risk.
View Article and Find Full Text PDF